The Exploration of the Pathogenesis and Treatments of Atherosclerosis
DOI:
https://doi.org/10.54097/93edyf91Keywords:
Atherosclerosis, Lipid Metabolism, Inflammation.Abstract
Atherosclerosis (AS) is a chronic disease that has complex pathogens. There have been many papers about AS until 2025 because of the serious consequences of it. The influences of cholesterol and Inflammatory factors are the core of many papers’ cores. Besides, the diagnostic and treatment methods are very important points in the application aspect. However, the new methods which are used in practice are still inequitable. This article analyzes the mechanism of AS and many important factors which can impact the process of AS, such as CRP, IL-6 and TNF-α. At the same time, the advanced methods of diagnosing and treating are also discussed in this article. LDL and HDL cholesterol can increase and decrease the risk of AS respectively, many inflammatory factors can aggravate the illness by promoting the increase of immune cells. The CT can be used to diagnose the disease, Colchicine, Methotrexate and Statins can control the process of AS.
Downloads
References
[1] GOU Yufen, WANG Hongyu. Advances in Immune Mechanisms and Treatment of Atherosclerosis. Adv Cardiovasc Dis, 2024, 45 (10): 912-917.
[2] Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: Successes, Surprises, and Future Challenges. Circ Res, 2016, 19; 118 (4): 531-4.
[3] Cheng J, Huang H, Chen Y, Wu R. Nanomedicine for Diagnosis and Treatment of Atherosclerosis. Adv Sci (Weinh), 2023, 10 (36): e2304294.
[4] Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 2018, 23;8 (3): 80.
[5] Remmerie A, Scott CL. Macrophages and lipid metabolism. Cell Immunol, 2018, 330: 27-42.
[6] Hartley A, Haskard D, Khamis R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy. Trends Cardiovasc Med, 2019, 29 (1): 22-26.
[7] Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm, 2013, 2013: 152786.
[8] Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res, 2010, 51 (8): 2058-73.
[9] Fransén K, Pettersson C, Hurtig-Wennlöf A. CRP levels are significantly associated with CRP genotype and estrogen use in The Lifestyle, Biomarker and Atherosclerosis (LBA) study. BMC Cardiovasc Disord, 2022, 15; 22 (1): 170.
[10] Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis, 2009, 19 (8): 521-4.
[11] Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol, 2021, 18 (1): 58-68.
[12] Bouchareychas L, Duong P, Covarrubias S, Alsop E, Phu TA, Chung A, Gomes M, Wong D, Meechoovet B, Capili A, Yamamoto R, Nakauchi H, McManus MT, Carpenter S, Van Keuren-Jensen K, Raffai RL. Macrophage Exosomes Resolve Atherosclerosis by Regulating Hematopoiesis and Inflammation via MicroRNA Cargo. Cell Rep, 2020, 14; 32 (2): 107881.
[13] McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol, 2009, 6 (6): 410-7.
[14] Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol, 2014, 7-14; 63 (1): 1-11.
[15] Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers, 2019, 16; 5 (1): 56.
[16] Kitagawa T, Nakano Y. Innovative atherosclerosis imaging using 18F-NaF PET/CT: Its clinical potential. J Nucl Cardiol, 2022, 29 (4): 1724-1728.
[17] Eckert J, Schmidt M, Magedanz A, Voigtländer T, Schmermund A. Coronary CT angiography in managing atherosclerosis. Int J Mol Sci, 2015, 9; 16 (2): 3740-56.
[18] González L, Bulnes JF, Orellana MP, Muñoz Venturelli P, Martínez Rodriguez G. The Role of Colchicine in Atherosclerosis: From Bench to Bedside. Pharmaceutics, 2022, 1; 14 (7): 1395.
[19] Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, Erre GL, Tommasi S. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Ther Adv Cardiovasc Dis, 2023, 17: 17539447231215213.
[20] Zhang H, Halmos B, Westerterp M. Statins for ACTA2 mutation-driven atherosclerosis? Eur Heart J, 2023, 1; 44 (29): 2727-2729.
[21] Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol, 2015, 8 (2): 189-99.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
